Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1997 Sep;44(3):289–291. doi: 10.1046/j.1365-2125.1997.00650.x

Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers

Dion R Brocks 1, James Upward 2, Maria Davy 2, Kate Howland 2, Christopher Compton 2, Charles McHugh 1, Michael J Dennis 1
PMCID: PMC2042846  PMID: 9296325

Abstract

Aims To study the magnitude of differences in the pharmacokinetics of pranlukast, after morning and evening administration.

Methods Pranlukast (300 mg) was administered to 12 healthy male volunteers on two separate occasions, either in the morning or evening. Both doses were given 30 min after a standard high fat content meal. Blood samples were collected up to 18 h postdose. Plasma was assayed by high performance liquid chromatography. Standard pharmacokinetic and statistical analyses were performed.

Results Statistically significant (P<0.05) increases were noted in AUC(o,t ) (56%) and tmax (2.5 h) after evening administration. Cmax was 14% higher after evening dosing (95% C.I. 0.71–1.84).

Conclusions Pranlukast bioavailability is apparently increased after evening dosing as compared with morning administration. Higher night-time and early morning plasma concentrations may confer additional therapeutic benefit at a time when asthmatics are at greatest risk of developing bronchospasm.

Keywords: chronopharmacokinetics, chronobiology, drug absorption, asthma, leukotrienes

Full Text

The Full Text of this article is available as a PDF (288.8 KB).


Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES